^
Association details:
| Biomarker: | SP140 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response
Published date:
12/13/2022
Excerpt:
We next evaluated the expression of SP140 in patients who were treated with anti-PD-1 immune-checkpoint inhibitors in HNSCC and non-small cell lung cancer (n=21). Samples were collected for gene expression analysis before treatment. A significantly higher level of SP140 was associated with response to anti-PD-1 immunotherapy, defined as stable disease or remission after anti-PD-1 treatment over 6 months (p<0.05).
DOI:
10.1136/jitc-2022-005088
